NOLASIBAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H22N2O3
Molecular Weight	338.4003
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO\N=C1\C[C@@H](CO)N(C1)C(=O)C2=CC=C(C=C2)C3=C(C)C=CC=C3

InChI

InChIKey=OLUJSZLBWZWGJT-HGBKYHTQSA-N

InChI=1S/C20H22N2O3/c1-14-5-3-4-6-19(14)15-7-9-16(10-8-15)20(24)22-12-17(21-25-2)11-18(22)13-23/h3-10,18,23H,11-13H2,1-2H3/b21-17-/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H22N2O3
Molecular Weight	338.4003
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: http://www.obseva.com/pipeline/nolasiban | https://www.ncbi.nlm.nih.gov/pubmed/28188254 | https://www.ncbi.nlm.nih.gov/pubmed/30962532

Erlosiban (OBE-001 or Nolasiban) is an oral oxytocin receptor antagonist. Erlosiban inhibits myometrium contractions and inflammation elicited by oxytocin. Erlosiban has the potential to decrease contractions and improve uterine blood flow hence enhancing the receptivity of the endometrium to embryo implantation. This may increase the rates of successful implantation, clinical pregnancy, and live-births among patients undergoing ART, or more specifically IVF procedures.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Oxytocin receptor 19 Target ID: P30559 Gene ID: 5021.0 Gene Symbol: OXTR Target Organism: Homo sapiens (Human) Sources: http://www.obseva.com/pipeline/nolasiban	Antagonist 2778

PubMed

Title	Date	PubMed
Effects of the Oral Oxytocin Receptor Antagonist Tocolytic OBE001 on Reproduction in Rats.	2016 Apr	26399985
Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor-Mediated Signaling in Human Amnion and Myometrium.	2017 Apr	28188254
Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F(2α)-induced Contractions and Inflammatory Responses in Human Myometrium.	2019 Apr 8	30962532

Patents

Sample Use Guides

In Vivo Use Guide

Phase III trials: 900 mg nolasiban as a single dose increased ongoing pregnancy and live birth rates

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:27:01 GMT 2023` Edited by `admin` on `Fri Dec 15 17:27:01 GMT 2023`
Record UNII	3765U8A1EC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NOLASIBAN

Official Name

English

nolasiban [INN]

Common Name

English

Nolasiban [WHO-DD]

Common Name

English

OBE-001

Code

English

OBE001

Code

English

((2S,4Z)-2-(HYDROXYMETHYL)-4-(METHOXYIMINO)PYRROLIDIN-1-YL)(2'-METHYL(1,1'-BIPHENYL)-4-YL)METHANONE

Systematic Name

English

3-PYRROLIDINONE, 5-(HYDROXYMETHYL)-1-((2'-METHYL(1,1'-BIPHENYL)-4-YL)CARBONYL)-, 3-(O-METHYLOXIME), (3Z,5S)-

Systematic Name

English

ERLOSIBAN

Common Name

English

Code System Code Type Description

SMS_ID

100000176871